What is Nuzyra used for?

Nuzyra is indicated for Community-Acquired Bacterial Pneumonia (CABP), Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

Nuzyra is developed by Paratek Pharms.

What development phase is Nuzyra in?

Nuzyra is FDA-approved (marketed).

What are the side effects of Nuzyra?

Common side effects include Alanine aminotransferase increased, Hypertension, Gamma-glutamyl transferase increased, Insomnia, Vomiting, Constipation.

What is the generic name of Nuzyra?

OMADACYCLINE TOSYLATE is the generic (nonproprietary) name of Nuzyra.

Last reviewed 2026-04-20 · How we verify

Nuzyra (OMADACYCLINE TOSYLATE)

Paratek Pharms · FDA-approved approved Small molecule Quality 56/100

Nuzyra works by inhibiting protein synthesis in bacteria, ultimately leading to their death.

Omadacycline tosylate (Nuzyra), marketed by Paratek Pharmaceuticals, is an advanced tetracycline antibiotic indicated for the treatment of community-acquired bacterial pneumonia (CABP). Its key strength lies in its mechanism of action, which effectively inhibits bacterial protein synthesis, offering a potent alternative to older tetracyclines like demeclocycline and doxycycline. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	OMADACYCLINE TOSYLATE
Sponsor	Paratek Pharms
Drug class	Tetracycline-class Antibacterial [EPC]
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	FDA-approved
First approval	2018

Mechanism of action

NUZYRA is an antibacterial drug [see Microbiology (12.4)].

Approved indications

Community-Acquired Bacterial Pneumonia (CABP)
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Common side effects

Alanine aminotransferase increased
Hypertension
Gamma-glutamyl transferase increased
Insomnia
Vomiting
Constipation
Nausea
Aspartate aminotransferase increased
Headache
Diarrhea
Fatigue
Dizziness

Drug interactions

Anticoagulant Drugs
Antacids containing aluminum, calcium, or magnesium
Bismuth subsalicylate
Iron-containing preparations

Patents

Patent	Expiry	Type





10111890	2037-08-03	Method of Use
8383610	2030-09-23	Compound
9314475	2031-03-18	Formulation

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
FDA Orange Book	Patents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nuzyra CI brief — competitive landscape report
Nuzyra updates RSS · CI watch RSS
Paratek Pharms portfolio CI